A Live Attenuated Chimeric West Nile Virus Vaccine, rWN/DEN4Δ30, Is Well Tolerated and Immunogenic in Flavivirus-Naive Older Adult Volunteers

J Infect Dis. 2017 Jan 1;215(1):52-55. doi: 10.1093/infdis/jiw501. Epub 2016 Oct 25.

Abstract

West Nile virus (WNV) is a major cause of mosquito-borne illness in the United States. Human disease ranges from mild febrile illness to severe fatal neurologic infection. Adults aged >60 years are more susceptible to neuroinvasive disease accompanied by a high mortality rate or long-lasting neurologic sequelae. A chimeric live attenuated West Nile virus vaccine, rWN/DEN4Δ30, was shown to be safe and immunogenic in healthy adults aged 18-50 years. This study evaluated rWN/DEN4Δ30 in flavivirus-naive adults aged 50-65 years and found it to be safe and immunogenic. Outbreaks of WNV infection tend to be unpredictable, and a safe and effective vaccine will be an important public health tool.

Keywords: West Nile virus; flavivirus; vaccine.

MeSH terms

  • Adult
  • Age Factors
  • Aged
  • Antibodies, Neutralizing / blood
  • Antibodies, Viral / blood
  • Disease Outbreaks
  • Female
  • Humans
  • Male
  • Middle Aged
  • Seroconversion
  • United States
  • Vaccines, Attenuated / administration & dosage
  • Vaccines, Attenuated / adverse effects
  • Vaccines, Attenuated / immunology
  • Viremia
  • West Nile Fever / epidemiology
  • West Nile Virus Vaccines / administration & dosage
  • West Nile Virus Vaccines / adverse effects*
  • West Nile Virus Vaccines / genetics
  • West Nile Virus Vaccines / immunology*
  • West Nile virus / immunology

Substances

  • Antibodies, Neutralizing
  • Antibodies, Viral
  • Vaccines, Attenuated
  • West Nile Virus Vaccines